Palvella Therapeutics (PVLA) Accumulated Expenses (2013 - 2026)
Palvella Therapeutics (PVLA) reported Accumulated Expenses of $675000.0 for Q1 2026, down 73.67% year-over-year from $2.6 million in Q1 2025, and down 84.49% on a QoQ basis from $4.4 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Accumulated Expenses data on file, last reported at $675000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 73.67% year-over-year to $675000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $675000.0 (down 73.67% YoY) and the FY2025 annual result came in at $4.4 million, down 20.52% from the prior year.
- Accumulated Expenses fell to $675000.0 in Q1 2026 per PVLA's latest filing, from $4.4 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $12.8 million in Q3 2023 and bottomed at $675000.0 in Q1 2026.
- The 5-year median for Accumulated Expenses is $3.5 million (2024), against an average of $4.4 million.
- Peak annual rise in Accumulated Expenses reached 292.98% in 2023, while the deepest fall reached 86.75% in 2023.
- Tracing PVLA's Accumulated Expenses over 5 years: stood at $10.7 million in 2022, then plunged by 86.75% to $1.4 million in 2023, then jumped by 284.41% to $5.5 million in 2024, then fell by 20.52% to $4.4 million in 2025, then sank by 84.49% to $675000.0 in 2026.
- Per Business Quant, the three latest PVLA Accumulated Expenses figures stand at $675000.0 (Q1 2026), $4.4 million (Q4 2025), and $4.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 675,000.00 |
| Dec 31, 2025 | 4.35 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | 786,000.00 |
| Mar 31, 2025 | 2.56 Mn |
| Dec 31, 2024 | 5.47 Mn |
| Sep 30, 2024 | 3.45 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Mar 31, 2024 | 6.02 Mn |
| Dec 31, 2023 | 1.42 Mn |
| Sep 30, 2023 | 12.76 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.68 Mn |
| Dec 31, 2022 | 10.75 Mn |
| Sep 30, 2022 | 3.25 Mn |
| Dec 31, 2021 | 16.84 Mn |
| Sep 30, 2021 | 19.69 Mn |
| Jun 30, 2021 | 16.08 Mn |
| Mar 31, 2021 | 9.56 Mn |
| Dec 31, 2020 | 7.73 Mn |
| Sep 30, 2020 | 7.49 Mn |
| Jun 30, 2020 | 5.94 Mn |
| Mar 31, 2020 | 6.94 Mn |
| Dec 31, 2019 | 9.94 Mn |
| Sep 30, 2019 | 7.17 Mn |
| Jun 30, 2019 | 8.49 Mn |
| Mar 31, 2019 | 9.22 Mn |
| Dec 31, 2018 | 9.11 Mn |
| Sep 30, 2018 | 5.98 Mn |
| Jun 30, 2018 | 4.56 Mn |
| Mar 31, 2018 | 6.58 Mn |
| Dec 31, 2017 | 6.17 Mn |
| Sep 30, 2017 | 5.10 Mn |
| Jun 30, 2017 | 6.35 Mn |
| Mar 31, 2017 | 2.96 Mn |
| Dec 31, 2016 | 3.72 Mn |
| Sep 30, 2016 | 2.90 Mn |
| Jun 30, 2016 | 2.33 Mn |
| Mar 31, 2016 | 2.32 Mn |
| Dec 31, 2015 | 1.74 Mn |
| Sep 30, 2015 | 480,626.00 |
| Jun 30, 2015 | 635,561.00 |
| Mar 31, 2015 | 413,395.00 |
| Dec 31, 2014 | 986,620.00 |
| Mar 31, 2014 | 2,500.00 |
| Dec 31, 2013 | 319,031.00 |